CRISPR Therapeutics’ (CRSP) “Neutral” Rating Reiterated at Cantor Fitzgerald

by · The Markets Daily

Cantor Fitzgerald reiterated their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note published on Wednesday morning,Benzinga reports. Cantor Fitzgerald also issued estimates for CRISPR Therapeutics’ FY2025 earnings at ($6.91) EPS.

Several other research analysts have also commented on the stock. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a research note on Wednesday, February 12th. Stifel Nicolaus lowered their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. JMP Securities reiterated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Morgan Stanley increased their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and an average price target of $74.40.

Read Our Latest Stock Report on CRSP

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $47.91 on Wednesday. The firm has a market cap of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67. The firm’s 50 day moving average price is $42.25 and its two-hundred day moving average price is $46.06. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities analysts anticipate that CRISPR Therapeutics will post -5.03 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the sale, the chief executive officer now owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC increased its holdings in CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after buying an additional 1,474,439 shares during the last quarter. Capital International Investors increased its holdings in CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after buying an additional 816,789 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in CRISPR Therapeutics by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock worth $150,029,000 after buying an additional 1,074,238 shares during the last quarter. State Street Corp increased its holdings in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after buying an additional 599,304 shares during the last quarter. Finally, FMR LLC increased its holdings in CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after buying an additional 23,075 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles